Payment overview · 2025
General Payments
$763.44
39 reported records · 19 companies
Healthcare provider profile · identity verified
David Desantis, M.D., PH.D
Allopathic & Osteopathic Physicians|Family Medicine · RICHMOND, IN · NPI 1467447748
Verified facts
What the public records show
CMS Open Payments records show David Desantis, M.D., PH.D received $763.44 in general payments during 2025 across 39 reported records.
Vanda Pharmaceuticals Inc. accounted for 26.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $198.71 | 26.0% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $75.31 | 9.9% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $67.67 | 8.9% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $51.37 | 6.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.19 | 6.7% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $41.70 | 5.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $37.93 | 5.0% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $30.32 | 4.0% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $27.71 | 3.6% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $27.33 | 3.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $24.08 | 3.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.05 | 3.0% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $20.70 | 2.7% | 1 | 2025 |
| CooperSurgical, Inc. | Unresolved — no canonical attribution shown | $18.35 | 2.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.66 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.42 | 2.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.46 | 1.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.23 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8.25 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $763.44 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $198.71 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $89.30 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $75.31 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $75.31 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $67.67 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.56 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.56 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $30.32 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $27.71 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $27.71 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| Paragard T 380A Normalized: paragard t 380a |
Drug | CooperSurgical, Inc. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $8.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
216 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 607 | 112 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 447 | 55 |
| Furosemide | Furosemide | 426 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 365 | 53 |
| Sertraline Hcl | Sertraline Hcl | 347 | 41 |
| Potassium Chloride | Potassium Chloride | 338 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 328 | 63 |
| Omeprazole | Omeprazole | 313 | 53 |
| Donepezil Hcl | Donepezil Hcl | 268 | 43 |
| Memantine Hcl | Memantine Hcl | 264 | 34 |
| Gabapentin | Gabapentin | 252 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 251 | 55 |
| Lisinopril | Lisinopril | 235 | 40 |
| Metformin Hcl | Metformin Hcl | 234 | 29 |
| Trazodone Hcl | Trazodone Hcl | 222 | 32 |
| Eliquis | Apixaban | 216 | 37 |
| Divalproex Sodium | Divalproex Sodium | 214 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 213 | 43 |
| Clonazepam | Clonazepam | 199 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 162 | 30 |
| Buspirone Hcl | Buspirone Hcl | 160 | 23 |
| Tramadol Hcl | Tramadol Hcl | 159 | 27 |
| Mirtazapine | Mirtazapine | 158 | 28 |
| Famotidine | Famotidine | 145 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 131 | 19 |
| Carvedilol | Carvedilol | 120 | 19 |
| Losartan Potassium | Losartan Potassium | 109 | 23 |
| Risperidone | Risperidone | 98 | 15 |
| Prednisone | Prednisone | 93 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 93 | 19 |
| Midodrine Hcl | Midodrine Hcl | 90 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 88 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 88 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 14 |
| Baclofen | Baclofen | 84 | 15 |
| Lorazepam | Lorazepam | 84 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 15 |
| Spironolactone | Spironolactone | 81 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 77 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | 12 |
| Pregabalin | Pregabalin | 74 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 13 |
| Alprazolam | Alprazolam | 65 | 14 |
| Levetiracetam | Levetiracetam | 65 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 63 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 59 | 19 |
| Allopurinol | Allopurinol | 56 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 56 | suppressed |
| Fentanyl | Fentanyl | 56 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 28 |
| Topiramate | Topiramate | 50 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 15 |
| Latanoprost | Latanoprost | 49 | suppressed |
| Nystatin | Nystatin | 48 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 23 |
| Loperamide | Loperamide Hcl | 46 | 18 |
| Sevelamer Carbonate | Sevelamer Carbonate | 46 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 15 |
| Jardiance | Empagliflozin | 45 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 44 | suppressed |
| Olanzapine | Olanzapine | 41 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 13 |
| Memantine Hcl Er | Memantine Hcl | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 40 | suppressed |
| Cephalexin | Cephalexin | 39 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 38 | 13 |
| Torsemide | Torsemide | 38 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 37 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | suppressed |
| Glimepiride | Glimepiride | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 16 |
| Azithromycin | Azithromycin | 32 | 21 |
| Galantamine Hbr | Galantamine Hbr | 32 | suppressed |
| Gemtesa | Vibegron | 32 | suppressed |
| Nystop | Nystatin | 32 | 16 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Brilinta | Ticagrelor | 31 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 31 | 13 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 29 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 11 |
| Admelog Solostar | Insulin Lispro | 28 | 15 |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 28 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Lacosamide | Lacosamide | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 25 | 11 |
| Scopolamine | Scopolamine | 25 | suppressed |
| Ziprasidone Mesylate | Ziprasidone Mesylate | 25 | suppressed |
| Acetic Acid | Acetic Acid | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 18 |
| Brimonidine Tartrate | Brimonidine Tartrate | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | suppressed |
| Paliperidone Er | Paliperidone | 22 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Hydroxyurea | Hydroxyurea | 20 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 20 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Daptomycin | Daptomycin | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Simvastatin | Simvastatin | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 14 |
| Primidone | Primidone | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Movantik | Naloxegol Oxalate | 16 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 12 |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 15 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Mupirocin | Mupirocin Calcium | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 12 |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Exelon | Rivastigmine | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Tobramycin Sulfate | Tobramycin Sulfate | 11 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $763.44 · 39 records | Vanda Pharmaceuticals Inc. | AIRSUPRA, AREXVY, ARISTADA, AUSTEDO XR, Auvelity, Azstarys, BEXSERO, CAPLYTA, Cologuard Collection Kit, FANAPT, INGREZZA, LINZESS, LYBALVI, NURTEC ODT, Paragard T 380A, QULIPTA, REXULTI, SHINGRIX, SUBLOCADE, UBRELVY, VOQUEZNA, ZAVZPRET, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error